 Paul Norman
Concepts (450)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptors, KIR | 53 | 2023 | 89 | 10.430 |
Why?
| | Killer Cells, Natural | 47 | 2023 | 381 | 6.690 |
Why?
| | Genes, MHC Class I | 12 | 2022 | 33 | 4.000 |
Why?
| | Histocompatibility Antigens Class I | 16 | 2023 | 177 | 3.720 |
Why?
| | HLA-C Antigens | 18 | 2023 | 32 | 3.350 |
Why?
| | Haplotypes | 35 | 2023 | 473 | 3.300 |
Why?
| | Alleles | 38 | 2023 | 832 | 2.830 |
Why?
| | Polymorphism, Genetic | 28 | 2023 | 642 | 2.410 |
Why?
| | HLA-B Antigens | 19 | 2022 | 55 | 2.370 |
Why?
| | HLA Antigens | 19 | 2023 | 230 | 2.330 |
Why?
| | Receptors, KIR3DL1 | 12 | 2022 | 15 | 2.310 |
Why?
| | Genotype | 33 | 2023 | 1882 | 2.210 |
Why?
| | Receptors, KIR2DL1 | 11 | 2020 | 17 | 2.100 |
Why?
| | Evolution, Molecular | 18 | 2022 | 454 | 1.990 |
Why?
| | HLA-A Antigens | 11 | 2023 | 50 | 1.470 |
Why?
| | Receptors, KIR3DS1 | 4 | 2022 | 6 | 1.410 |
Why?
| | Immunogenetics | 4 | 2023 | 5 | 1.370 |
Why?
| | Selection, Genetic | 11 | 2019 | 252 | 1.290 |
Why?
| | High-Throughput Nucleotide Sequencing | 12 | 2021 | 453 | 1.280 |
Why?
| | Genetic Variation | 16 | 2022 | 926 | 1.140 |
Why?
| | Genes, MHC Class II | 2 | 2017 | 72 | 1.120 |
Why?
| | Receptors, Immunologic | 8 | 2021 | 209 | 1.080 |
Why?
| | Immunogenetic Phenomena | 2 | 2022 | 6 | 0.970 |
Why?
| | Multimorbidity | 1 | 2023 | 29 | 0.930 |
Why?
| | Pre-Eclampsia | 3 | 2020 | 183 | 0.890 |
Why?
| | Herpesviridae | 1 | 2022 | 20 | 0.860 |
Why?
| | Ligands | 14 | 2023 | 567 | 0.860 |
Why?
| | Receptors, Natural Killer Cell | 6 | 2022 | 16 | 0.860 |
Why?
| | Gene Frequency | 15 | 2021 | 513 | 0.850 |
Why?
| | Primates | 3 | 2019 | 114 | 0.820 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2023 | 702 | 0.810 |
Why?
| | Herpesviridae Infections | 1 | 2023 | 142 | 0.810 |
Why?
| | Communicable Diseases | 1 | 2023 | 132 | 0.800 |
Why?
| | Histocompatibility Antigens Class II | 3 | 2023 | 355 | 0.750 |
Why?
| | Genome, Human | 5 | 2017 | 387 | 0.740 |
Why?
| | Genetics, Population | 10 | 2021 | 207 | 0.710 |
Why?
| | Humans | 108 | 2023 | 118972 | 0.710 |
Why?
| | Genome-Wide Association Study | 4 | 2023 | 1323 | 0.700 |
Why?
| | Peptides | 4 | 2022 | 879 | 0.680 |
Why?
| | Point Mutation | 3 | 2017 | 228 | 0.650 |
Why?
| | Heterozygote | 1 | 2019 | 262 | 0.640 |
Why?
| | Pan troglodytes | 9 | 2017 | 57 | 0.640 |
Why?
| | Complement C4 | 1 | 2017 | 26 | 0.600 |
Why?
| | Protein Binding | 10 | 2019 | 1975 | 0.600 |
Why?
| | Leukemia | 1 | 2019 | 208 | 0.590 |
Why?
| | Receptors, KIR2DL4 | 2 | 2016 | 3 | 0.590 |
Why?
| | Mucins | 1 | 2017 | 59 | 0.590 |
Why?
| | Immunoglobulin Fc Fragments | 2 | 2015 | 35 | 0.540 |
Why?
| | Polymorphism, Single Nucleotide | 13 | 2021 | 2062 | 0.530 |
Why?
| | Exons | 1 | 2016 | 307 | 0.520 |
Why?
| | Population | 1 | 2014 | 30 | 0.500 |
Why?
| | Receptors, KIR2DL2 | 5 | 2021 | 6 | 0.470 |
Why?
| | Receptors, KIR2DL3 | 6 | 2017 | 8 | 0.470 |
Why?
| | Linkage Disequilibrium | 7 | 2017 | 273 | 0.460 |
Why?
| | Malaria | 1 | 2013 | 60 | 0.450 |
Why?
| | Cell Line | 8 | 2019 | 2707 | 0.440 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1308 | 0.410 |
Why?
| | DNA Copy Number Variations | 3 | 2021 | 167 | 0.410 |
Why?
| | Genetic Predisposition to Disease | 8 | 2021 | 2275 | 0.390 |
Why?
| | Molecular Sequence Data | 14 | 2014 | 2871 | 0.380 |
Why?
| | Behcet Syndrome | 2 | 2021 | 17 | 0.370 |
Why?
| | Biological Evolution | 5 | 2019 | 443 | 0.370 |
Why?
| | Epitopes | 8 | 2019 | 443 | 0.360 |
Why?
| | Hematopoietic Stem Cell Transplantation | 4 | 2021 | 540 | 0.350 |
Why?
| | Amino Acid Sequence | 9 | 2019 | 2071 | 0.350 |
Why?
| | Meiosis | 1 | 2009 | 60 | 0.350 |
Why?
| | Immunoglobulins | 3 | 2023 | 154 | 0.350 |
Why?
| | Recombination, Genetic | 2 | 2010 | 173 | 0.340 |
Why?
| | Genotyping Techniques | 3 | 2019 | 75 | 0.340 |
Why?
| | Models, Molecular | 5 | 2019 | 1435 | 0.340 |
Why?
| | Antigens, CD | 4 | 2017 | 460 | 0.330 |
Why?
| | Phylogeny | 12 | 2017 | 816 | 0.320 |
Why?
| | Immunity, Innate | 6 | 2019 | 745 | 0.310 |
Why?
| | Signal Transduction | 3 | 2019 | 4709 | 0.290 |
Why?
| | Immune System | 2 | 2019 | 181 | 0.290 |
Why?
| | Multigene Family | 3 | 2018 | 200 | 0.290 |
Why?
| | Egypt | 2 | 2023 | 10 | 0.290 |
Why?
| | Amino Acid Substitution | 5 | 2016 | 276 | 0.280 |
Why?
| | Codon | 2 | 2016 | 89 | 0.270 |
Why?
| | Genomics | 5 | 2021 | 706 | 0.270 |
Why?
| | Parkinson Disease | 2 | 2020 | 334 | 0.270 |
Why?
| | Sequence Analysis, DNA | 7 | 2018 | 755 | 0.260 |
Why?
| | Minority Groups | 2 | 2019 | 237 | 0.260 |
Why?
| | Animals | 26 | 2023 | 33381 | 0.250 |
Why?
| | Hominidae | 2 | 2019 | 99 | 0.250 |
Why?
| | HLA-DP beta-Chains | 1 | 2023 | 78 | 0.230 |
Why?
| | Immunity, Cellular | 1 | 2005 | 270 | 0.230 |
Why?
| | Gene Dosage | 3 | 2021 | 136 | 0.220 |
Why?
| | Iran | 2 | 2020 | 37 | 0.220 |
Why?
| | Leukocytes | 1 | 2004 | 290 | 0.220 |
Why?
| | Centromere | 2 | 2015 | 43 | 0.220 |
Why?
| | Lymphocyte Activation | 5 | 2021 | 1067 | 0.220 |
Why?
| | Sequence Alignment | 3 | 2021 | 336 | 0.220 |
Why?
| | Africa, Southern | 2 | 2021 | 8 | 0.210 |
Why?
| | China | 2 | 2021 | 175 | 0.210 |
Why?
| | Major Histocompatibility Complex | 1 | 2023 | 220 | 0.210 |
Why?
| | Thymus Gland | 1 | 2023 | 300 | 0.210 |
Why?
| | Longevity | 1 | 2023 | 151 | 0.210 |
Why?
| | Toll-Like Receptor 3 | 1 | 2021 | 31 | 0.210 |
Why?
| | Health | 1 | 2022 | 81 | 0.210 |
Why?
| | Yersinia pestis | 1 | 2021 | 34 | 0.200 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2023 | 310 | 0.200 |
Why?
| | Genomic Structural Variation | 1 | 2021 | 7 | 0.200 |
Why?
| | Female | 27 | 2021 | 61564 | 0.200 |
Why?
| | Plague | 1 | 2021 | 42 | 0.200 |
Why?
| | Histocompatibility Testing | 3 | 2017 | 123 | 0.200 |
Why?
| | Malaysia | 1 | 2020 | 4 | 0.200 |
Why?
| | Protein Interaction Domains and Motifs | 2 | 2019 | 138 | 0.200 |
Why?
| | HLA-D Antigens | 1 | 2021 | 36 | 0.190 |
Why?
| | Male | 23 | 2021 | 57801 | 0.190 |
Why?
| | Pregnancy | 6 | 2020 | 5690 | 0.190 |
Why?
| | Psoriasis | 1 | 2021 | 76 | 0.190 |
Why?
| | Arabs | 1 | 2020 | 4 | 0.190 |
Why?
| | HLA-DRB1 Chains | 2 | 2019 | 97 | 0.180 |
Why?
| | Natural Cytotoxicity Triggering Receptor 2 | 1 | 2019 | 2 | 0.180 |
Why?
| | Clathrin Heavy Chains | 1 | 2019 | 2 | 0.180 |
Why?
| | Protozoan Infections | 1 | 2019 | 11 | 0.180 |
Why?
| | HLA-DP Antigens | 1 | 2019 | 33 | 0.180 |
Why?
| | Telomere | 3 | 2014 | 204 | 0.170 |
Why?
| | Phylogeography | 1 | 2019 | 45 | 0.170 |
Why?
| | Base Sequence | 3 | 2016 | 2159 | 0.170 |
Why?
| | Indians, North American | 2 | 2015 | 598 | 0.170 |
Why?
| | Africa South of the Sahara | 2 | 2019 | 37 | 0.160 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2018 | 48 | 0.160 |
Why?
| | Indians, South American | 2 | 2009 | 23 | 0.160 |
Why?
| | Cytomegalovirus | 2 | 2017 | 144 | 0.160 |
Why?
| | ZAP-70 Protein-Tyrosine Kinase | 1 | 2017 | 8 | 0.160 |
Why?
| | Syk Kinase | 1 | 2017 | 16 | 0.160 |
Why?
| | T-Lymphocytes | 2 | 2016 | 1774 | 0.160 |
Why?
| | Multifactorial Inheritance | 1 | 2019 | 143 | 0.160 |
Why?
| | Structure-Activity Relationship | 1 | 2019 | 522 | 0.160 |
Why?
| | Binding Sites | 6 | 2015 | 1224 | 0.150 |
Why?
| | Contig Mapping | 1 | 2017 | 10 | 0.150 |
Why?
| | Pan paniscus | 1 | 2017 | 6 | 0.150 |
Why?
| | Immunodominant Epitopes | 1 | 2017 | 27 | 0.150 |
Why?
| | Pongo | 1 | 2017 | 6 | 0.150 |
Why?
| | Flow Cytometry | 6 | 2018 | 1085 | 0.150 |
Why?
| | Protein Structure, Tertiary | 5 | 2015 | 823 | 0.150 |
Why?
| | Women's Health | 1 | 2019 | 274 | 0.150 |
Why?
| | Gene Expression Regulation | 2 | 2013 | 2445 | 0.150 |
Why?
| | Virus Diseases | 1 | 2019 | 198 | 0.150 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 102 | 0.150 |
Why?
| | Open Reading Frames | 1 | 2017 | 121 | 0.140 |
Why?
| | State Medicine | 1 | 2016 | 21 | 0.140 |
Why?
| | Reference Standards | 1 | 2017 | 176 | 0.140 |
Why?
| | Herpesvirus 4, Human | 1 | 2017 | 126 | 0.140 |
Why?
| | HIV-1 | 1 | 2022 | 776 | 0.140 |
Why?
| | Gene Flow | 2 | 2015 | 79 | 0.140 |
Why?
| | Nephroblastoma Overexpressed Protein | 1 | 2016 | 1 | 0.140 |
Why?
| | Molecular Typing | 1 | 2016 | 18 | 0.140 |
Why?
| | B-Lymphocytes | 3 | 2017 | 770 | 0.140 |
Why?
| | Placentation | 2 | 2016 | 43 | 0.140 |
Why?
| | Protein Conformation | 1 | 2019 | 848 | 0.140 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2015 | 25 | 0.140 |
Why?
| | Sf9 Cells | 1 | 2015 | 9 | 0.140 |
Why?
| | Donor Selection | 1 | 2016 | 73 | 0.130 |
Why?
| | Spodoptera | 1 | 2015 | 37 | 0.130 |
Why?
| | Baculoviridae | 1 | 2015 | 46 | 0.130 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2015 | 47 | 0.130 |
Why?
| | Gene Expression | 4 | 2018 | 1489 | 0.130 |
Why?
| | Human Migration | 1 | 2015 | 21 | 0.130 |
Why?
| | Case-Control Studies | 8 | 2021 | 3171 | 0.130 |
Why?
| | Research Report | 1 | 2015 | 75 | 0.130 |
Why?
| | Insecta | 1 | 2015 | 68 | 0.130 |
Why?
| | Amino Acid Motifs | 5 | 2019 | 200 | 0.130 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2016 | 118 | 0.130 |
Why?
| | Polynesia | 1 | 2014 | 4 | 0.130 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2021 | 532 | 0.130 |
Why?
| | Simian Immunodeficiency Virus | 1 | 2015 | 98 | 0.130 |
Why?
| | Biological Assay | 1 | 2015 | 122 | 0.130 |
Why?
| | Receptors, KIR3DL2 | 2 | 2015 | 2 | 0.130 |
Why?
| | New Zealand | 1 | 2014 | 50 | 0.130 |
Why?
| | Isoantibodies | 1 | 1995 | 63 | 0.120 |
Why?
| | Fluoridation | 1 | 2014 | 5 | 0.120 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 292 | 0.120 |
Why?
| | Incidence | 1 | 2020 | 2424 | 0.120 |
Why?
| | Fluorides | 1 | 2014 | 47 | 0.120 |
Why?
| | Kidney Transplantation | 2 | 2003 | 585 | 0.120 |
Why?
| | Glucose | 1 | 2019 | 953 | 0.120 |
Why?
| | DNA | 3 | 2021 | 1388 | 0.120 |
Why?
| | Residence Characteristics | 1 | 2016 | 299 | 0.120 |
Why?
| | Protein Folding | 1 | 2015 | 250 | 0.120 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2015 | 632 | 0.120 |
Why?
| | Noise | 1 | 2014 | 67 | 0.120 |
Why?
| | Chromosomes, Human, Pair 19 | 2 | 2004 | 25 | 0.120 |
Why?
| | Mammals | 1 | 2015 | 253 | 0.120 |
Why?
| | United Kingdom | 3 | 2014 | 236 | 0.120 |
Why?
| | Cytomegalovirus Infections | 1 | 2015 | 187 | 0.110 |
Why?
| | Phenotype | 5 | 2017 | 3003 | 0.110 |
Why?
| | Conserved Sequence | 2 | 2011 | 219 | 0.110 |
Why?
| | Osteosarcoma | 1 | 2014 | 71 | 0.110 |
Why?
| | Hearing Aids | 1 | 2014 | 68 | 0.110 |
Why?
| | Hematopoietic Stem Cells | 1 | 2016 | 359 | 0.110 |
Why?
| | Species Specificity | 4 | 2017 | 565 | 0.110 |
Why?
| | Metagenomics | 1 | 2014 | 134 | 0.110 |
Why?
| | Sarcoma, Ewing | 1 | 2014 | 65 | 0.110 |
Why?
| | Seals, Earless | 1 | 2012 | 3 | 0.110 |
Why?
| | Tinnitus | 1 | 2014 | 61 | 0.110 |
Why?
| | Exome | 1 | 2014 | 220 | 0.110 |
Why?
| | Genetics, Medical | 3 | 2019 | 26 | 0.110 |
Why?
| | Saliva | 1 | 2014 | 188 | 0.110 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 4552 | 0.110 |
Why?
| | Hepatitis C | 1 | 2015 | 217 | 0.110 |
Why?
| | Adult | 12 | 2021 | 31512 | 0.110 |
Why?
| | Drinking Water | 1 | 2014 | 68 | 0.110 |
Why?
| | Graft Survival | 1 | 1995 | 504 | 0.110 |
Why?
| | Models, Genetic | 3 | 2015 | 595 | 0.110 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2020 | 968 | 0.110 |
Why?
| | Polymerase Chain Reaction | 4 | 2017 | 1012 | 0.100 |
Why?
| | CD56 Antigen | 2 | 2009 | 34 | 0.100 |
Why?
| | Guideline Adherence | 1 | 2016 | 523 | 0.100 |
Why?
| | Environment | 1 | 2013 | 346 | 0.100 |
Why?
| | Bone Neoplasms | 1 | 2014 | 199 | 0.100 |
Why?
| | Lymphocyte Subsets | 2 | 2009 | 76 | 0.100 |
Why?
| | Hospitals | 1 | 2016 | 598 | 0.100 |
Why?
| | Smoking | 1 | 2019 | 1487 | 0.100 |
Why?
| | Men's Health | 1 | 2011 | 8 | 0.100 |
Why?
| | Graft Rejection | 1 | 1995 | 555 | 0.100 |
Why?
| | Genes, Overlapping | 1 | 2011 | 2 | 0.100 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily C | 3 | 2017 | 8 | 0.100 |
Why?
| | Occupational Exposure | 1 | 2014 | 277 | 0.100 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2011 | 35 | 0.100 |
Why?
| | Interferon-gamma | 2 | 2017 | 736 | 0.100 |
Why?
| | Hybridization, Genetic | 1 | 2011 | 79 | 0.100 |
Why?
| | Hearing Loss | 1 | 2014 | 186 | 0.100 |
Why?
| | Immunoglobulin G | 1 | 1995 | 788 | 0.100 |
Why?
| | Healthcare Disparities | 1 | 2016 | 496 | 0.100 |
Why?
| | Europe | 2 | 2021 | 356 | 0.090 |
Why?
| | Homocysteine | 1 | 2011 | 137 | 0.090 |
Why?
| | North America | 2 | 2021 | 266 | 0.090 |
Why?
| | Organ Transplantation | 1 | 2013 | 165 | 0.090 |
Why?
| | Mass Spectrometry | 1 | 2013 | 681 | 0.090 |
Why?
| | Gene Conversion | 1 | 2009 | 7 | 0.090 |
Why?
| | Transplantation, Homologous | 3 | 2016 | 415 | 0.090 |
Why?
| | Gene Products, nef | 1 | 2009 | 13 | 0.090 |
Why?
| | Receptors, IgG | 2 | 2014 | 67 | 0.090 |
Why?
| | Myocardial Infarction | 1 | 2016 | 968 | 0.090 |
Why?
| | Child | 4 | 2019 | 19129 | 0.090 |
Why?
| | Cohort Studies | 4 | 2021 | 5116 | 0.080 |
Why?
| | Antigens, Bacterial | 1 | 2009 | 116 | 0.080 |
Why?
| | Africa | 3 | 2019 | 100 | 0.080 |
Why?
| | Histocompatibility Antigens | 1 | 2009 | 102 | 0.080 |
Why?
| | Cell Differentiation | 3 | 2019 | 1753 | 0.080 |
Why?
| | HIV Infections | 1 | 2022 | 2459 | 0.080 |
Why?
| | Mutagenesis, Site-Directed | 4 | 2009 | 363 | 0.080 |
Why?
| | Exotoxins | 1 | 2007 | 15 | 0.080 |
Why?
| | Middle Aged | 11 | 2021 | 27617 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2020 | 2220 | 0.080 |
Why?
| | Osteoarthritis, Knee | 1 | 2010 | 223 | 0.080 |
Why?
| | Receptors, Fc | 1 | 2007 | 48 | 0.070 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2007 | 372 | 0.070 |
Why?
| | Tissue Donors | 3 | 2017 | 336 | 0.070 |
Why?
| | Cognition Disorders | 1 | 2011 | 529 | 0.070 |
Why?
| | Immunoglobulin A | 1 | 2007 | 174 | 0.070 |
Why?
| | Genetic Loci | 2 | 2019 | 281 | 0.070 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2674 | 0.070 |
Why?
| | Cell Line, Tumor | 4 | 2015 | 2851 | 0.070 |
Why?
| | Jurkat Cells | 2 | 2019 | 134 | 0.070 |
Why?
| | Microsatellite Repeats | 1 | 2004 | 143 | 0.060 |
Why?
| | Histocompatibility | 1 | 2003 | 27 | 0.060 |
Why?
| | HeLa Cells | 2 | 2015 | 583 | 0.060 |
Why?
| | Leukocyte Immunoglobulin-like Receptor B1 | 1 | 2003 | 2 | 0.060 |
Why?
| | Polymorphism, Single-Stranded Conformational | 1 | 2003 | 30 | 0.060 |
Why?
| | Staphylococcus aureus | 1 | 2007 | 394 | 0.060 |
Why?
| | Granzymes | 1 | 2023 | 40 | 0.060 |
Why?
| | Cell Communication | 1 | 2005 | 281 | 0.060 |
Why?
| | Lymphocytes | 1 | 2005 | 347 | 0.060 |
Why?
| | Human Immunodeficiency Virus Proteins | 1 | 2022 | 6 | 0.060 |
Why?
| | Viral Regulatory and Accessory Proteins | 1 | 2022 | 28 | 0.050 |
Why?
| | Gene Library | 2 | 2014 | 127 | 0.050 |
Why?
| | DNA Primers | 2 | 2018 | 533 | 0.050 |
Why?
| | Cloning, Molecular | 2 | 2014 | 546 | 0.050 |
Why?
| | Software Design | 1 | 2021 | 23 | 0.050 |
Why?
| | Databases, Nucleic Acid | 1 | 2021 | 36 | 0.050 |
Why?
| | Hydroxychloroquine | 1 | 2021 | 59 | 0.050 |
Why?
| | Age Factors | 4 | 2014 | 2995 | 0.050 |
Why?
| | Software | 2 | 2018 | 613 | 0.050 |
Why?
| | Bacterial Proteins | 1 | 2007 | 759 | 0.050 |
Why?
| | Homozygote | 1 | 2021 | 190 | 0.050 |
Why?
| | Aging | 1 | 2011 | 1670 | 0.050 |
Why?
| | Twins | 1 | 2001 | 247 | 0.050 |
Why?
| | Oceania | 1 | 2019 | 2 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 625 | 0.040 |
Why?
| | Mutation | 3 | 2020 | 3457 | 0.040 |
Why?
| | Cytotoxicity Tests, Immunologic | 2 | 2009 | 49 | 0.040 |
Why?
| | Celiac Disease | 1 | 2002 | 267 | 0.040 |
Why?
| | Nucleic Acid Denaturation | 1 | 2018 | 30 | 0.040 |
Why?
| | Hepatitis B | 1 | 2019 | 52 | 0.040 |
Why?
| | England | 2 | 2016 | 68 | 0.040 |
Why?
| | Limit of Detection | 1 | 2018 | 55 | 0.040 |
Why?
| | Disease Models, Animal | 3 | 2016 | 3730 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2017 | 4077 | 0.040 |
Why?
| | Body Height | 1 | 2019 | 187 | 0.040 |
Why?
| | Recurrence | 1 | 2021 | 975 | 0.040 |
Why?
| | Health Equity | 1 | 2019 | 56 | 0.040 |
Why?
| | Arthritis, Rheumatoid | 1 | 2006 | 989 | 0.040 |
Why?
| | Autophagy | 1 | 2021 | 315 | 0.040 |
Why?
| | Workflow | 1 | 2018 | 148 | 0.040 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily K | 1 | 2017 | 4 | 0.040 |
Why?
| | Butyrophilins | 1 | 2017 | 5 | 0.040 |
Why?
| | Time Factors | 4 | 2006 | 6412 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2018 | 345 | 0.040 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2017 | 20 | 0.040 |
Why?
| | Gorilla gorilla | 1 | 2017 | 22 | 0.040 |
Why?
| | Computational Biology | 1 | 2021 | 588 | 0.040 |
Why?
| | Graft vs Host Disease | 1 | 2019 | 216 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2020 | 569 | 0.040 |
Why?
| | Sex Factors | 3 | 2014 | 1781 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2019 | 209 | 0.040 |
Why?
| | Computer Simulation | 1 | 2021 | 922 | 0.040 |
Why?
| | Antibodies, Monoclonal | 2 | 2018 | 1284 | 0.040 |
Why?
| | Spatial Analysis | 1 | 2016 | 25 | 0.040 |
Why?
| | Liver | 1 | 2005 | 1816 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2017 | 134 | 0.040 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2017 | 73 | 0.040 |
Why?
| | DNA Mutational Analysis | 1 | 2017 | 381 | 0.030 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2016 | 46 | 0.030 |
Why?
| | Pancreatic Elastase | 1 | 2016 | 74 | 0.030 |
Why?
| | Purinergic P2Y Receptor Antagonists | 1 | 2016 | 62 | 0.030 |
Why?
| | Logistic Models | 1 | 2021 | 1901 | 0.030 |
Why?
| | Autoantibodies | 1 | 2023 | 1335 | 0.030 |
Why?
| | CD57 Antigens | 1 | 2015 | 14 | 0.030 |
Why?
| | Elastin | 1 | 2016 | 77 | 0.030 |
Why?
| | Siberia | 1 | 2015 | 9 | 0.030 |
Why?
| | Americas | 1 | 2015 | 23 | 0.030 |
Why?
| | K562 Cells | 1 | 2015 | 73 | 0.030 |
Why?
| | Angiotensin II | 1 | 2016 | 107 | 0.030 |
Why?
| | Leukemia, Myeloid | 1 | 2015 | 42 | 0.030 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2008 | 204 | 0.030 |
Why?
| | History, Ancient | 1 | 2015 | 58 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2001 | 984 | 0.030 |
Why?
| | Adaptive Immunity | 1 | 2016 | 161 | 0.030 |
Why?
| | Feces | 2 | 2015 | 396 | 0.030 |
Why?
| | DNA Damage | 1 | 2017 | 357 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 627 | 0.030 |
Why?
| | Virus Activation | 1 | 2015 | 80 | 0.030 |
Why?
| | South Africa | 1 | 2015 | 163 | 0.030 |
Why?
| | Terminology as Topic | 1 | 2016 | 211 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2019 | 290 | 0.030 |
Why?
| | Chromosomes, Mammalian | 1 | 2014 | 26 | 0.030 |
Why?
| | Databases, Genetic | 1 | 2016 | 253 | 0.030 |
Why?
| | United States | 2 | 2023 | 12555 | 0.030 |
Why?
| | Genetic Fitness | 1 | 2015 | 55 | 0.030 |
Why?
| | Speech Reception Threshold Test | 1 | 2014 | 3 | 0.030 |
Why?
| | Myocardial Ischemia | 1 | 2016 | 251 | 0.030 |
Why?
| | Gene Deletion | 1 | 2016 | 361 | 0.030 |
Why?
| | Bone Marrow Transplantation | 1 | 2015 | 244 | 0.030 |
Why?
| | Small-Area Analysis | 1 | 2014 | 9 | 0.030 |
Why?
| | Caribbean Region | 1 | 2013 | 24 | 0.030 |
Why?
| | Mouth | 1 | 2014 | 74 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 255 | 0.030 |
Why?
| | Transplant Recipients | 1 | 2015 | 148 | 0.030 |
Why?
| | Echocardiography | 1 | 2016 | 556 | 0.030 |
Why?
| | Reproduction | 1 | 2015 | 189 | 0.030 |
Why?
| | Registries | 1 | 2021 | 1810 | 0.030 |
Why?
| | Hepacivirus | 1 | 2015 | 230 | 0.030 |
Why?
| | Aspirin | 1 | 2016 | 334 | 0.030 |
Why?
| | Aged | 5 | 2016 | 19657 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2015 | 262 | 0.030 |
Why?
| | Chromosome Mapping | 1 | 2014 | 510 | 0.030 |
Why?
| | Mice | 2 | 2023 | 15520 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2015 | 371 | 0.030 |
Why?
| | Pandemics | 1 | 2021 | 1355 | 0.030 |
Why?
| | Risk Factors | 2 | 2019 | 9000 | 0.030 |
Why?
| | Demography | 1 | 2013 | 274 | 0.030 |
Why?
| | Ursidae | 1 | 2012 | 12 | 0.030 |
Why?
| | Acute Disease | 1 | 2015 | 940 | 0.030 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2016 | 402 | 0.030 |
Why?
| | Host-Pathogen Interactions | 1 | 2015 | 300 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2016 | 6561 | 0.030 |
Why?
| | DNA, Mitochondrial | 1 | 2013 | 187 | 0.030 |
Why?
| | Cell Membrane | 1 | 2016 | 710 | 0.030 |
Why?
| | Genome | 1 | 2014 | 277 | 0.030 |
Why?
| | Swimming Pools | 1 | 1991 | 6 | 0.030 |
Why?
| | Cryptosporidiosis | 1 | 1991 | 11 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2013 | 481 | 0.030 |
Why?
| | Quantitative Trait Loci | 1 | 2014 | 324 | 0.030 |
Why?
| | Sewage | 1 | 1991 | 26 | 0.030 |
Why?
| | Cattle | 1 | 2014 | 978 | 0.030 |
Why?
| | Pregnancy Proteins | 1 | 2011 | 38 | 0.030 |
Why?
| | Diet | 1 | 2019 | 1153 | 0.030 |
Why?
| | Immunologic Memory | 1 | 2013 | 313 | 0.030 |
Why?
| | Dogs | 1 | 2012 | 371 | 0.030 |
Why?
| | Biomarkers | 1 | 2021 | 3588 | 0.020 |
Why?
| | Algorithms | 1 | 2018 | 1541 | 0.020 |
Why?
| | Adaptation, Biological | 1 | 2011 | 57 | 0.020 |
Why?
| | HLA-A2 Antigen | 1 | 2011 | 39 | 0.020 |
Why?
| | Population Surveillance | 1 | 2014 | 413 | 0.020 |
Why?
| | Uterus | 1 | 2011 | 194 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2014 | 405 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 1995 | 1795 | 0.020 |
Why?
| | HLA-A11 Antigen | 1 | 2009 | 1 | 0.020 |
Why?
| | Culture | 1 | 2011 | 129 | 0.020 |
Why?
| | HLA-A24 Antigen | 1 | 2009 | 2 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1129 | 0.020 |
Why?
| | Australia | 1 | 2010 | 212 | 0.020 |
Why?
| | Antibody Affinity | 1 | 2009 | 55 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2275 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2016 | 2680 | 0.020 |
Why?
| | Receptors, KIR2DL5 | 1 | 2009 | 1 | 0.020 |
Why?
| | Leucine | 1 | 2009 | 117 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 1991 | 322 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2009 | 371 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 2009 | 338 | 0.020 |
Why?
| | Tryptophan | 1 | 2009 | 139 | 0.020 |
Why?
| | Models, Biological | 1 | 2016 | 1715 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 248 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2009 | 422 | 0.020 |
Why?
| | Young Adult | 2 | 2014 | 10793 | 0.020 |
Why?
| | Disease Progression | 1 | 2015 | 2490 | 0.020 |
Why?
| | Odds Ratio | 1 | 2011 | 996 | 0.020 |
Why?
| | Prevalence | 1 | 2014 | 2326 | 0.020 |
Why?
| | Radiography | 1 | 2010 | 861 | 0.020 |
Why?
| | Lysine | 1 | 2009 | 248 | 0.020 |
Why?
| | Peptide Fragments | 1 | 2011 | 702 | 0.020 |
Why?
| | Venezuela | 1 | 2006 | 7 | 0.020 |
Why?
| | Microbiota | 1 | 2014 | 656 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2011 | 814 | 0.020 |
Why?
| | Myeloid Cells | 1 | 2007 | 128 | 0.020 |
Why?
| | Rabbits | 1 | 2007 | 780 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 1995 | 4596 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2006 | 224 | 0.020 |
Why?
| | Placenta | 1 | 2011 | 638 | 0.020 |
Why?
| | CD4-CD8 Ratio | 1 | 2005 | 19 | 0.020 |
Why?
| | CD8 Antigens | 1 | 2005 | 71 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2005 | 76 | 0.020 |
Why?
| | Microspheres | 1 | 2005 | 130 | 0.020 |
Why?
| | Immunophenotyping | 1 | 2005 | 278 | 0.020 |
Why?
| | Cell Separation | 1 | 2005 | 296 | 0.010 |
Why?
| | Asia | 1 | 2003 | 54 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1158 | 0.010 |
Why?
| | Oligonucleotide Probes | 1 | 2003 | 53 | 0.010 |
Why?
| | Adolescent | 3 | 2014 | 18480 | 0.010 |
Why?
| | Infant | 2 | 2014 | 8293 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2009 | 1055 | 0.010 |
Why?
| | Cyclosporine | 1 | 2003 | 173 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2014 | 5255 | 0.010 |
Why?
| | Postoperative Period | 1 | 2003 | 309 | 0.010 |
Why?
| | Child, Preschool | 2 | 2014 | 9491 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 2001 | 136 | 0.010 |
Why?
| | Cytokines | 1 | 2009 | 1900 | 0.010 |
Why?
| | Living Donors | 1 | 2003 | 319 | 0.010 |
Why?
| | Twins, Dizygotic | 1 | 2001 | 182 | 0.010 |
Why?
| | Twins, Monozygotic | 1 | 2001 | 214 | 0.010 |
Why?
| | Chi-Square Distribution | 1 | 2001 | 525 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2003 | 681 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2001 | 1474 | 0.010 |
Why?
| | Cryptosporidium | 1 | 1991 | 12 | 0.010 |
Why?
| | Interviews as Topic | 1 | 1991 | 599 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 1991 | 4708 | 0.000 |
Why?
|
|
Norman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|